Mycosis Fungoides

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mycosis Fungoides

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides 57 11 19 42 75 53 43 14 36 16 71 31 33
Mycosis Fungoides Lymphoma 11 75
Alibert-Bazin Syndrome 19 42
Granuloma Fungoides 19 42
Mycosis Fungoides, Alibert-Bazin Type 58
Classic Mycosis Fungoides 58



Mycosis Fungoides: Familial aggregation without simple mendelian pattern 57
Classic Mycosis Fungoides: Multigenic/multifactorial 58


Classic Mycosis Fungoides: 1-9/1000000 (Europe) 58

Age Of Onset:

Classic Mycosis Fungoides: Adult 58


Orphanet: 58  
Rare skin diseases
Rare haematological diseases

Summaries for Mycosis Fungoides

MedlinePlus Genetics: 42 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.Mycosis fungoides may progress slowly through several stages, although not all people with the condition progress through all stages. Most affected individuals initially develop skin lesions called patches, which are flat, scaly, pink or red areas on the skin that can be itchy. Cancerous T cells, which cause the formation of patches, are found in these lesions. The skin cells themselves are not cancerous; the skin problems result when cancerous T cells move from the blood into the skin. Patches are most commonly found on the lower abdomen, upper thighs, buttocks, and breasts. They can disappear and reappear or remain stable over time. In some affected individuals, patches progress to plaques, the next stage of mycosis fungoides.Plaques are raised lesions that are usually reddish, purplish, or brownish in color and itchy. Plaques commonly occur in the same body regions as patches. While some plaques arise from patches, others develop on their own, and an affected person can have both patches and plaques simultaneously. As with patches, cancerous T cells are found in plaques. Plaques can remain stable or can develop into tumors. Not everyone with patches or plaques develops tumors.The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than plaques. They can arise from patches or plaques or occur on their own. Mycosis fungoides was so named because the tumors can resemble mushrooms, a type of fungus. Common locations for tumor development include the upper thighs and groin, breasts, armpits, and the crook of the elbow. Open sores may develop on the tumors, often leading to infection.Although rare, the cancerous T cells can spread to other organs, including the lymph nodes, spleen, liver, and lungs. Spread to other organs can occur in any stage of mycosis fungoides but is most common in the tumor stage. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer.

MalaCards based summary: Mycosis Fungoides, also known as mycosis fungoides lymphoma, is related to lymphoproliferative syndrome, x-linked, 1 and lymphoma. An important gene associated with Mycosis Fungoides is CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Denileukin diftitox and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and bone marrow, and related phenotypes are dry skin and neoplasm of the skin

OMIM®: 57 Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400) (Updated 08-Dec-2022)

GARD: 19 Mycosis fungoides is a disease in which T-cell lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin.

Orphanet: 58 Classical mycosis fungoides is the most common type of mycosis fungoides (MF; see this term), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques and eventually to tumors.

Wikipedia: 75 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Related Diseases for Mycosis Fungoides

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 lymphoproliferative syndrome, x-linked, 1 32.6 TNFRSF8 TIA1 CXCR3 CCR4
2 lymphoma 32.2 TNFRSF8 TIA1 STAT3 IL2RA IL2 CDKN2B
3 parapsoriasis 32.1 TNFRSF8 CD7
4 primary cutaneous t-cell non-hodgkin lymphoma 32.0 TNFRSF8 TIA1 STAT3 ITGAE IL2RA IL2
5 follicular mucinosis 31.9 TNFRSF8 TIA1 CD7
6 burkitt lymphoma 31.8 TNFRSF8 STAT3 IFNA1 CDKN2B
7 sezary's disease 31.8 TNFRSF8 TNFRSF1B TIA1 STAT3 IL2RA IL2
8 lymphoproliferative syndrome 31.7 TNFRSF8 TIA1 STAT3 IL2 CTLA4
9 exanthem 31.6 IL2 IFNA1 CTLA4
10 anaplastic large cell lymphoma 31.6 TNFRSF8 STAT3 IL2RA CXCR3 CCR4 CCL17
11 dermatitis 31.6 STAT3 IL2 CXCR3 CXCL9 CTLA4 CCR4
12 contact dermatitis 31.6 IL2 CXCR3 CXCL9 CCR4 CCL22 CCL17
13 b-cell lymphoma 31.6 TNFRSF8 TIA1 STAT3 CXCR3 CDKN2B
14 hypereosinophilic syndrome 31.4 STAT3 IL2RA IL2 IFNA2 IFNA1 CCL17
15 lymphoma, hodgkin, classic 31.4 TNFRSF8 TIA1 STAT3 IL2RA IL2 CD28
16 lichen planus 31.4 IL2 CXCR3 CXCL9
17 adult t-cell leukemia/lymphoma 31.4 TNFRSF8 IL2RA IL2 CTLA4 CD7 CCR4
18 t-cell acute lymphoblastic leukemia 31.4 TNFRSF8 STAT3 IL2RA IL2 CD7 CD28
19 peripheral t-cell lymphoma 31.3 TNFRSF8 TIA1 STAT3 IL2RA CXCR3 CD7
20 herpes zoster 31.3 IL2 IFNA2 IFNA1
21 dermatitis, atopic 31.3 TNFRSF8 STAT3 IL2RA IL2 CXCR3 CXCL9
22 alopecia areata 31.3 IL2RA IL2 CXCR3 CXCL9 CTLA4
23 allergic contact dermatitis 31.2 IL2 CXCR3 CXCL9 CCR4 CCL22 CCL17
24 spongiotic dermatitis 31.2 TNFRSF8 CD7
25 lymphoma, non-hodgkin, familial 31.2 TNFRSF8 STAT3 IL2RA IL2 CTLA4 CDKN2B
26 allergic disease 31.2 IL2 CD28 CCL22 CCL17
27 lymphopenia 31.2 IL2RA IL2 CTLA4 CCL22
28 angioimmunoblastic t-cell lymphoma 31.1 TNFRSF8 TIA1 CD7
29 t-cell adult acute lymphocytic leukemia 31.1 TNFRSF8 TIA1 IL2 CD7 CCR4
30 sarcoidosis 1 31.1 TNFRSF1B IL2RA IL2 CXCR3 CXCL9 CD28
31 melanoma 31.1 STAT3 IL2 IFNA2 IFNA1 CXCR3 CTLA4
32 nasal type extranodal nk/t-cell lymphoma 31.1 TNFRSF8 TIA1
33 psoriasis 30.9 TNFRSF1B STAT3 IL2RA IL2 DPP4 CXCR3
34 skin disease 30.9 TNFRSF8 STAT3 ITGAE IL2 IFNA1 DPP4
35 skin sarcoidosis 30.9 IL2 IFNA1 CTLA4
36 uveitis 30.9 IL2RA IL2 IFNA2 CXCR3 CTLA4
37 acute graft versus host disease 30.9 IL2RA IL2
38 leukemia, chronic myeloid 30.8 STAT3 IL2 IFNA2 IFNA1 CTLA4 CDKN2B
39 diphtheria 30.8 IL2RA IL2 IFNA1
40 peripheral nervous system disease 30.8 TNFRSF8 STAT3 IL2 IFNA1 DPP4 CTLA4
41 mature t-cell and nk-cell lymphoma 30.8 TNFRSF8 TIA1 STAT3 IL2 CTLA4 CD7
42 lymphoblastic lymphoma 30.8 TNFRSF8 CDKN2B CD7
43 leukemia, chronic lymphocytic 30.8 TNFRSF8 STAT3 ITGAE IL2RA IL2 IFNA1
44 thrombocytopenia 30.7 STAT3 IL2 IFNA2 IFNA1 CTLA4 CDKN2B
45 chickenpox 30.7 IL2 IFNA1 CTLA4
46 hairy cell leukemia 30.7 ITGAE IL2RA IL2 IFNA2 IFNA1
47 leukemia, acute lymphoblastic 30.7 IL2 CXCR3 CTLA4 CDKN2B CD7 CD28
48 lymphadenitis 30.7 IL2RA CXCR3 CXCL9 CCL22
49 primary cutaneous gamma-delta t-cell lymphoma 30.7 TNFRSF8 TIA1 CD7
50 lymphomatoid granulomatosis 30.6 TIA1 IFNA2 IFNA1 CXCL9

Graphical network of the top 20 diseases related to Mycosis Fungoides:

Diseases related to Mycosis Fungoides

Symptoms & Phenotypes for Mycosis Fungoides

Human phenotypes related to Mycosis Fungoides:

58 30 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin 58 30 Hallmark (90%) Very frequent (99-80%)
2 neoplasm of the skin 58 30 Hallmark (90%) Very frequent (99-80%)
3 erythema 58 30 Hallmark (90%) Very frequent (99-80%)
4 skin rash 58 30 Hallmark (90%) Very frequent (99-80%)
5 eczema 58 30 Hallmark (90%) Very frequent (99-80%)
6 pruritus 58 30 Hallmark (90%) Very frequent (99-80%)
7 skin plaque 58 30 Hallmark (90%) Very frequent (99-80%)
8 abnormal lymphocyte morphology 58 30 Hallmark (90%) Very frequent (99-80%)
9 alopecia 58 30 Frequent (33%) Frequent (79-30%)
10 hypopigmented skin patches 58 30 Frequent (33%) Frequent (79-30%)
11 irregular hyperpigmentation 58 30 Frequent (33%) Frequent (79-30%)
12 lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
13 poikiloderma 58 30 Frequent (33%) Frequent (79-30%)
14 cutaneous t-cell lymphoma 58 30 Frequent (33%) Frequent (79-30%)
15 splenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
16 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
17 abnormality of the nail 58 30 Occasional (7.5%) Occasional (29-5%)
18 hyperkeratosis 58 30 Occasional (7.5%) Occasional (29-5%)
19 skin ulcer 58 30 Occasional (7.5%) Occasional (29-5%)
20 abnormal eyelid morphology 58 30 Occasional (7.5%) Occasional (29-5%)
21 abnormality of bone marrow cell morphology 58 30 Occasional (7.5%) Occasional (29-5%)
22 edema 58 30 Occasional (7.5%) Occasional (29-5%)
23 lymphoma 58 30 Very frequent (99-80%)
24 psoriasiform dermatitis 30 HP:0003765

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Skin Nails Hair Skin:
psoriasiform dermatitis
malignant t-cell skin lymphoma
skin scaling

Clinical features from OMIM®:

254400 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 CCL17 CCL22 CCR10 CCR4 CD28 CD7
2 no effect GR00402-S-2 10.14 CCL22 CCR10 CCR4 CD28 CD7 CDKN2B

MGI Mouse Phenotypes related to Mycosis Fungoides:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.16 CCL17 CCL22 CCR10 CCR4 CD28 CD7
2 endocrine/exocrine gland MP:0005379 10 CCR10 CD28 CD7 CDKN2B CTLA4 DPP4
3 respiratory system MP:0005388 9.65 CCR4 CTLA4 CXCR3 DPP4 IFNA1 IFNA2
4 hematopoietic system MP:0005397 9.6 CCL17 CCR10 CCR4 CD28 CD7 CDKN2B

Drugs & Therapeutics for Mycosis Fungoides

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5 Pharmaceutical Solutions Phase 4
6 interferons Phase 4
7 Folic Acid Antagonists Phase 4
8 Folate Phase 4
9 Vitamin B9 Phase 4
10 Vitamin B Complex Phase 4
11 Interferon alpha-2 Phase 4
12 Interferon-alpha Phase 4
Clorazepate Dipotassium Phase 4
Brentuximab vedotin Approved, Investigational Phase 3 914088-09-8
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
Hypericin Investigational Phase 3 548-04-9 5281051
Zanolimumab Investigational Phase 3 652153-01-0
19 Antiviral Agents Phase 3
20 Anti-Infective Agents Phase 3
21 Immunosuppressive Agents Phase 3
22 Immunologic Factors Phase 3
23 Dermatologic Agents Phase 3
24 Furocoumarins Phase 3
25 Psychotropic Drugs Phase 3
26 Antidepressive Agents Phase 3
27 Antineoplastic Agents, Immunological Phase 3
28 Immunoglobulins Phase 3
29 Antibodies Phase 3
30 Antibodies, Monoclonal Phase 3
31 Opiate Alkaloids Phase 3
32 Narcotic Antagonists Phase 3
33 Narcotics Phase 3
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
Petrolatum Approved, Investigational Phase 2 8009-03-8
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
Melphalan Approved Phase 2 148-82-3 4053 460612
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
2 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
3 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
4 Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
5 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Terminated NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
6 Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial Unknown status NCT03454945 Phase 3 Vibramycin
7 A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB Completed NCT01686594 Phase 3 8-methoxypsoralen
8 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
9 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Completed NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
10 TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides: a Prospective Randomized Controlled Study Not yet recruiting NCT05205902 Phase 3
11 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
12 A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3 bexarotene;methoxypsoralen
13 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Terminated NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
14 A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT03278782 Phase 1, Phase 2 Romidepsin
15 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
16 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
17 Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial Unknown status NCT02943642 Phase 2 Vorinostat
18 Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Unknown status NCT02881749 Phase 2 mechlorethamine gel 0.016%
19 A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT) Unknown status NCT02542124 Phase 2
20 A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome Completed NCT02243579 Phase 2
21 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
22 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
23 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Completed NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
24 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
25 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
26 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
27 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
28 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
29 A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine
30 An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response Completed NCT00535470 Phase 2 0.04% Mechlorethamine gel
31 A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF) Completed NCT00168064 Phase 2 mechlorethamine-MCH (nitrogen mustard)
32 A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis Completed NCT00099255 Phase 2 SGN-30
33 A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H Completed NCT00047060 Phase 1, Phase 2 cyclosporine;fludarabine;Campath
34 A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides Completed NCT01073267 Phase 2
35 Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy Completed NCT00074087 Phase 2 pegylated liposomal doxorubicin hydrochloride
36 Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome Completed NCT00057967 Phase 2
37 Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
38 Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
39 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
40 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
41 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
42 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
43 Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies Completed NCT00038376 Phase 2 Isotretinoin (Accutane);Interferon Alpha
44 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
45 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
46 Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas Completed NCT00185965 Phase 1, Phase 2 CPG 7909
47 Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
48 Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
49 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
50 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 71 / NDF-RT 50 :

etoposide phosphate
Interferon Alfa-2a
Interferon Alfa-2b
interferon alfacon-1
Interferon gamma-1b
Mechlorethamine hydrochloride
Methotrexate Sodium
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Uracil Mustard
Vinblastine Sulfate

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: mycosis fungoides

Genetic Tests for Mycosis Fungoides

Anatomical Context for Mycosis Fungoides

Organs/tissues related to Mycosis Fungoides:

MalaCards : Skin, T Cells, Bone Marrow, Liver, Spleen, Bone, Myeloid

Publications for Mycosis Fungoides

Articles related to Mycosis Fungoides:

(show top 50) (show all 6723)
# Title Authors PMID Year
Lymphomas and leukemias in the relatives of patients with mycosis fungoides. 62 57
7055783 1982
Familial mycosis fungoides revisited. 62 57
7425665 1980
Mycosis fungoides of prolonged duration in siblings. 62 57
5246760 1968
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. 57
26551670 2015
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. 57
26551667 2015
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. 53 62
20212249 2010
Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. 53 62
19242508 2009
Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. 53 62
19289586 2009
Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants. 53 62
19220628 2009
Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy. 53 62
19956431 2009
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 53 62
19239991 2008
The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. 53 62
18644018 2008
The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. 53 62
18089499 2008
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 53 62
17975162 2007
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. 53 62
17367611 2007
CD13 and TCR clone: markers of early mycosis fungoides. 53 62
17340024 2007
Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. 53 62
16931956 2006
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 53 62
16741518 2006
Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. 53 62
16859899 2006
CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides. 53 62
16713487 2006
Immunogold detection of CD3 and CD4 antigens in patients with Mycosis fungoides. 53 62
17013537 2006
Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. 53 62
16197392 2005
CCR10 is expressed in cutaneous T-cell lymphoma. 53 62
15700309 2005
Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. 53 62
15927812 2005
Concurrent mycosis fungoides and precursor B cell lymphoblastic lymphoma in a 6-year-old child. 53 62
15660892 2005
Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. 53 62
15328201 2004
Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. 53 62
14708605 2003
Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. 53 62
12393570 2003
Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. 53 62
12522366 2003
Clusterin expression in malignant lymphomas: a survey of 266 cases. 53 62
12429802 2002
Relative content of cytokines in different tissues in mycosis fungoides. 53 62
12459845 2002
Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. 53 62
12209749 2002
Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. 53 62
11874489 2002
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). 53 62
11908715 2002
Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. 53 62
11720171 2001
Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. 53 62
11453809 2001
Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. 53 62
11392886 2001
Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). 53 62
11359391 2001
The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. 53 62
11242798 2001
Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a. 53 62
11340297 2001
Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. 53 62
11707858 2000
IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. 53 62
10949545 2000
Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. 53 62
10887135 2000
Lack of membrane expression of interleukin-2 receptor alpha chain (CD25) in mycosis fungoides: application of laser scanning cytometry for phenotyping of skin infiltrating lymphocytes. 53 62
10777356 2000
Interferon-alpha-associated development of bullous lesions in mycosis fungoides. 53 62
10681616 2000
Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. 53 62
10602042 2000
Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. 53 62
10504456 1999
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. 53 62
10374878 1999
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 53 62
10233762 1999
Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. 53 62
10233858 1999

Variations for Mycosis Fungoides

Expression for Mycosis Fungoides

Search GEO for disease gene expression data for Mycosis Fungoides.

Pathways for Mycosis Fungoides

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.91 CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
Show member pathways
Show member pathways
13.47 CCL17 CCL22 CCR10 CCR4 CD28 CDKN2B
Show member pathways
Show member pathways
Show member pathways
13.13 CCL17 CCL22 CCR10 CCR4 CD28 CXCL9
Show member pathways
Show member pathways
Show member pathways
12.83 CCL17 CCL22 CCR10 CCR4 CXCL9 CXCR3
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.21 CD28 CTLA4 IL2 IL2RA
Show member pathways
12.13 STAT3 IL2RA IL2 CD28
Show member pathways
11.98 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
18 11.96 CD28 IFNA2 IL2 IL2RA
Show member pathways
11.95 STAT3 IL2RA IL2
Show member pathways
11.94 STAT3 IL2RA IL2
Show member pathways
11.9 STAT3 IL2RA IL2
22 11.88 TNFRSF1B STAT3 CCL22
Show member pathways
11.84 STAT3 IL2 CD28
24 11.84 CD28 CTLA4 CXCL9 IL2 IL2RA
25 11.73 ITGAE IL2RA IL2 CXCR3 CD7
26 11.69 ITGAE IL2 IFNA2
27 11.66 STAT3 IL2RA IL2
Show member pathways
11.64 IL2RA IL2 CTLA4
29 11.51 TNFRSF1B IL2RA IL2 CD28
30 11.49 STAT3 IL2RA CTLA4
31 11.47 TNFRSF1B STAT3 CCL22
32 11.43 IL2RA IL2 CD28 CCL22 CCL17
Show member pathways
34 11.31 TNFRSF1B IL2RA IL2 CD28
35 11.2 IFNA1 CXCL9 CD28
36 11.19 STAT3 IL2RA IL2 CD28
37 11.16 IL2 CTLA4 CD28
38 10.96 ITGAE IL2 CXCL9 CCL22 CCL17
39 10.94 IL2RA CTLA4
40 10.85 CTLA4 CD28
41 10.71 IL2RA IL2 CTLA4
42 10.65 IL2RA IL2

GO Terms for Mycosis Fungoides

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.53 ITGAE IL2RA CXCR3 CXCL9 CTLA4 CD28
2 protein complex involved in cell adhesion GO:0098636 9.26 CTLA4 CD28

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 10.16 CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
2 cell-cell signaling GO:0007267 10.16 IL2 IFNA2 CXCL9 CCL22 CCL17
3 positive regulation of cytosolic calcium ion concentration GO:0007204 10.13 IL2 CXCR3 CCR4 CCR10
4 inflammatory response GO:0006954 10.11 CCL17 CCL22 CCR4 CXCL9 CXCR3 IFNA2
5 humoral immune response GO:0006959 10.04 IFNA2 IFNA1 CD28
6 T cell activation GO:0042110 10.02 DPP4 CD7 CD28
7 chemotaxis GO:0006935 10 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
8 defense response GO:0006952 9.95 STAT3 IFNA2 IFNA1 CXCL9
9 cell chemotaxis GO:0060326 9.95 CXCR3 CCR4 CCR10 CCL22
10 positive regulation of T cell proliferation GO:0042102 9.88 IL2RA IL2 CD28
11 activated T cell proliferation GO:0050798 9.86 IL2RA IL2
12 regulation of T cell homeostatic proliferation GO:0046013 9.73 IL2RA IL2
13 chemokine-mediated signaling pathway GO:0070098 9.73 CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
14 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2RA IL2
15 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.67 IL2 IL2RA
16 immune response GO:0006955 9.64 CCL17 CCL22 CCR10 CCR4 CD28 CD7
17 regulation of T cell proliferation GO:0042129 9.62 TNFRSF1B CTLA4 CD28
18 lymphocyte proliferation GO:0046651 9.54 IL2RA IL2

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.8 CXCL9 CCL22 CCL17
2 C-C chemokine binding GO:0019957 9.73 CXCR3 CCR4 CCR10
3 C-C chemokine receptor activity GO:0016493 9.63 CXCR3 CCR4 CCR10
4 chemokine receptor activity GO:0004950 9.35 CXCR3 CCR4 CCR10
5 cytokine activity GO:0005125 9.32 IL2 IFNA2 IFNA1 CXCL9 CCL22 CCL17

Sources for Mycosis Fungoides

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....